Possibilities of personalized pharmacotherapy and medical rehabilitation of patients with long COVID from the perspective of clinical metabolomics

Introduction. The material presents the results of the study of the effectiveness of the drug Ethylmethylhydroxypyridine malate in  patients with long COVID, based on the  dynamics of  clinical manifestations and metabolomic parameters responsible for the level of oxidative stress.
Aim. Evaluation of efficacy and registration of adverse reactions of ethylmethylhydroxypyridine malate administration to decrease oxidative stress level and reduce symptoms of asthenia and cognitive disorders in patients with long COVID.
Materials and methods. 24 patients diagnosed with U09.9 “Condition after COVID-19 unspecified” were included in a non-randomized controlled prospective study, Patients were divided into 2  groups of  12  each. The experimental group received Ethylmethylhydroxypyridine malate tablets chewable 100 mg in a dosage of 400 mg/day. Clinical assessment by scales (mMRC dyspnea scale; 6-minute walk test  (6MWT); MFI-20  subjective asthenia assessment scale; Montreal Cognitive Assessment Scale (MoCA); Barthel Baseline Functional Activity Rating Scale), and determination of metabolomic parameters were performed on days 1 and 14–18 of the study.
Results. Use of the drug ethylmethylhydroxypyridine malate in patients with long COVID, led to a decrease in the level of oxidative stress, and normalization of  mitochondrial function, as well as more pronounced improvements of  the clinical picture. According to the scale of evaluation of asthenia (MFI-20) in the group of patients who received ethylmethylhydroxypyridine malate improvement of 21% was noted, in the control group improvement of 13% was noted. According to cognitive impairment assessment scale (MoCA), the drug group showed 20% improvement, while the control group showed 12,5% improvement.
Conclusion. The drug ethylmethylhydroxypyridine malate tablets chewable 100 mg in a dosage of 400 mg/day demonstrates clinical efficacy characterized by, among other things, a decrease in oxidative stress, as well as clinical safety due to the absence of development of adverse reactions in patients with long COVID.

1. Han Q., Zheng B., Daines L., Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022;11(2):269. https://doi.org/10.3390/pathogens11020269.

2. Lechner-Scott J., Levy M., Hawkes C., Yeh A., Giovannoni G. Long COVID or post COVID-19 syndrome. Mult Scler Relat Disord. 2021;55:103268. https://doi.org/10.1016/j.msard.2021.103268.

3. Fugazzaro S., Contri A., Esseroukh O., Kaleci S., Croci S., Massari M. et al. Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. Int J Environ Res Public Health. 2022;19(9):5185. https://doi.org/10.3390/ijerph19095185.

4. Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. https://doi.org/10.1038/s41598-021-95565-8.

5. Xu E., Xie Y., Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28(11):2406–2415. https://doi.org/10.1038/s41591-022-02001-z.

6. Vollbracht C., Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol. 2022;13:899198. https://doi.org/10.3389/fphar.2022.899198.

7. Chernyak B.V., Popova E.N., Prikhodko A.S., Grebenchikov O.A., Zinovkina L.A., Zinovkin R.A. COVID-19 and Oxidative Stress. Biochemistry (Moscow). 2020;85(12):1543–1553. https://doi.org/10.1134/S0006297920120068.

8. Montiel V., Lobysheva I., Gérard L., Vermeersch M., Perez-Morga D., Castelein T. et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022;77:103893. https://doi.org/10.1016/j.ebiom.2022.103893.

9. Wu J., Zhao M., Li C., Zhang Y., Wang D.W. The SARS-CoV-2 induced targeted amino acid profiling in patients at hospitalized and convalescent stage. Biosci Rep. 2021;41(3):BSR20204201. https://doi.org/10.1042/BSR20204201.

10. Pan Y., Cheng J.H., Sun D.W. Metabolomic analyses on microbial primary and secondary oxidative stress responses. Compr Rev Food Sci Food Saf. 2021;20(6):5675–5697. https://doi.org/10.1111/1541-4337.12835.

11. Archakov A.I., Kukes V.G., Dmitriev D.A. (eds.). The results of the study of the domestic drug, the 2nd generation antioxidant – ethoxidol. Moscow: MAKFiF; 2014. 90 p. (In Russ.)

12. Kukes V.G., Parfenova O.K., Sidorov N.G., Olefir Yu.V., Gazdanova A.А. Oxidative stress and inflammation in COVID-19 pathogenesis. Medical Journal of the Russian Federation. 2020;26(4):244–247. (In Russ.) https://doi.org/10.17816/0869-2106-2020-26-4-244-247.

13. Goroshko O.A., Novikov K.N., Kukes V.G., Voeikov V.L., Arkhipov V.V., Buravleva E.V. et al. Correction of oxidative stress in patients with chronic cerebral ischemia. Clinical Medicine (Russian Journal). 2016;94(7):549–553. (In Russ.) https://doi.org/10.18821/0023-2149-2016-94-7-549-553.

14. Wójcik O.P., Koenig K.L., Zeleniuch-Jacquotte A., Costa M., Chen Y. The potential protective effects of taurine on coronary heart disease. Atherosclerosis. 2010;208(1):19–25. https://doi.org/10.1016/j.atherosclerosis.2009.06.002.

15. Garg U., Smith L.D. Biomarkers Inborn Errors of Metabolism: Clinical Aspects and Laboratory Determination. Elsevier; 2017. 476 p. https://doi.org/10.1016/C2014-0-03841-5.

16. Wu N., Yang M., Gaur U., Xu H., Yao Y., Li D. Alpha-Ketoglutarate: Physiological Functions and Applications. Biomol Ther (Seoul). 2016;24(1):1–8. https://doi.org/10.4062/biomolther.2015.078.